Medical Technology

@xconomy.com 3 years ago

Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs

@xconomy.com 3 years ago

FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures

@xconomy.com 3 years ago

Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally

@xconomy.com 3 years ago

Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact

@xconomy.com 4 years ago

Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further

@xconomy.com 5 years ago

CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M

@xconomy.com 5 years ago

Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M

@xconomy.com 5 years ago

Six Life Science Firms Close Q3 with an IPO, More Are on the Way

@xconomy.com 5 years ago

Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug

@xconomy.com 5 years ago

Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision

@xconomy.com 5 years ago

With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines

@xconomy.com 5 years ago

Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M